Alternative drug therapies for dementia
1University of Pittsburg School of Medicine, Western Psychiatric Institute and Clinic, Pittsburg, Pennsylvania 15213, USA. HowlandRH@upmc.edu
Summary
Current Alzheimer's disease treatments offer limited benefits. Investigational therapies, including vasodilators, antioxidants, and anti-inflammatories, lack sufficient evidence for widespread clinical use in dementia treatment.
Area of Science:
- Neurology
- Pharmacology
- Geriatrics
Background:
- Approved Alzheimer's disease (AD) medications, such as acetylcholinesterase inhibitors and memantine, provide modest benefits.
- The limited efficacy of current AD drugs necessitates exploration of alternative therapeutic strategies.
- Historical and emerging hypotheses for dementia pathogenesis, including cerebrovascular insufficiency and oxidative stress, guide drug development.
Purpose of the Study:
- To review the current landscape of FDA-approved and investigational drugs for Alzheimer's disease.
- To evaluate the evidence supporting various alternative drug therapies for dementia.
- To assess the safety and efficacy of potential treatments beyond standard AD pharmacotherapy.
Main Methods:
- Literature review of FDA-approved medications for Alzheimer's disease.
- Examination of clinical evidence for vasodilator, antioxidant, and anti-inflammatory agents in dementia.
- Analysis of data on other drug classes, including vitamins and hormone therapies, for treating cognitive decline.
Main Results:
- Approved drugs like isoxsuprine and ergoloid mesylates for dementia have limited supporting evidence and are infrequently used.
- Investigational approaches targeting free radicals (antioxidants) and inflammation have not yet demonstrated sufficient efficacy or safety.
- Other therapies, including vitamin E, statins, omega-3 fatty acids, and hormone therapies, lack robust evidence for treating dementing disorders.
Conclusions:
- Current pharmacologic options for Alzheimer's disease offer limited clinical benefits.
- Numerous alternative drug therapies investigated for dementia, including vasodilators and antioxidants, lack substantial evidence of efficacy and safety.
- Further research is required to identify effective and safe treatments for Alzheimer's disease and other dementias.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...